Bentley Systems, Guidewire Software, Health Catalyst, and Doximity Shares Skyrocket, What You Need To Know

The headline beats for these software stocks are real, but the market's reaction tells the deeper story. This is a classic game of expectations versus reality, where a good print can still disappoint if it doesn't exceed the whisper number, and strong guidance can be overshadowed by a reset of future growth.

For Doximity, the setup was a textbook "sell the news" event. The company posted a solid Q3 EPS beat of 46 cents and topped revenue estimates, showing resilience in its core subscription business. Yet shares plunged 38.5% in after-hours trading the moment the report landed. The reason is clear: the good news was instantly overshadowed by weak guidance. Management projected Q4 revenue of $143M–$144M, missing Wall Street's $148M estimate and signaling a sharp slowdown. This guidance reset, driven by delayed pharma budgets, reset the forward view and told investors that the recent growth momentum was not sustainable. The beat was already priced in; the guidance reset was the new reality.

Bentley Systems presents a different dynamic. The company delivered a clean beat on both top and bottom lines, with revenue of $391.6 million and adjusted EPS of $0.27 both surpassing consensus. Yet the stock's performance was lackluster, with shares down about 14.9% since the start of the year. This suggests the strong quarterly results were already expected. The market had likely baked in the company's steady subscription growth and margin expansion, as evidenced by its constant currency ARR growth rate of 11.5% and improving operating margins. Without a surprise or a meaningful guidance raise, the beat was simply the baseline for the stock to hold its ground.

Health Catalyst's situation is one of extreme pessimism. The stock is trading near its 52-week low, a clear signal that the market has not yet priced in any positive catalyst. The recent earnings report, which showed a beat on the top line, was met with a muted reaction because the company's forward outlook remains under pressure. The expectation gap here is wide: the market is pricing in continued struggles, leaving little room for disappointment but also little room for a near-term pop unless the company delivers a dramatic turnaround.

Guidewire Software, by contrast, is seeing its stock jump on pure optimism. Shares are up 6% on strong volume, fueled by the anticipation of its upcoming earnings report. The catalyst is the company's impressive cloud ARR growth of 22%, which demonstrates the strength of its transition to the subscription model. This growth is being priced in ahead of the official report, creating a "buy the rumor" dynamic. The market is betting that the upcoming print will confirm the positive trajectory, turning the whisper number into a reality.

The Guidance Reset: Where Forward-Looking Statements Created the Expectation Gap

The divergence between market expectations and reality for these stocks was not set by the past quarter's results alone, but by the forward-looking statements that followed. These guidance updates and outlooks reset the trajectory, creating the expectation gap that drove the subsequent moves.

For Doximity, the guidance reset was immediate and severe. The company's Q3 beat was instantly overshadowed by its projection for Q4 revenue of $143M–$144M. That figure implied just 4% growth, missing Wall Street's $148M estimate by a wide margin. The market's reaction-a 30% single-day plunge-was a direct response to this reset. The forward view now signaled a sharp slowdown, driven by delayed pharma budgets. This guidance miss told investors that the recent growth momentum was not sustainable, turning a good print into a sell-the-news event.

Bentley Systems, by contrast, provided a more stable but perhaps less exciting outlook. The company's guidance for 2026 points to continued strong ARR growth, with its constant currency ARR growth rate already at 11.5%. Yet the market's muted reaction suggests that even this steady expansion may be the new baseline, not a surprise. The forward-looking statement here is one of continuity, which, in a market pricing in consistent execution, may not be enough to drive the stock higher. The expectation gap is not in the direction of growth, but in its pace relative to what the market now anticipates.

Guidewire Software is the purest case of forward-looking optimism. The stock's recent jump is fueled by anticipation of its upcoming report, which is scheduled for March 5, 2026. The market is looking past the past quarter's performance to the forward view. The key metric to watch is its cloud ARR growth of 22%. This number is being priced in ahead of the official print, creating a "buy the rumor" dynamic. The expectation is that the upcoming report will confirm this positive trajectory, turning the whisper number into reality and justifying the current optimism.

Health Catalyst's situation is defined by a lack of a positive forward view. The stock's downtrend suggests the market is pricing in continued challenges, with no clear catalyst to shift sentiment. The forward-looking statements from the company have not yet provided a compelling reason to believe in a near-term turnaround. As a result, the expectation gap is wide and negative: the market is not pricing in any improvement, leaving the stock vulnerable to further disappointment unless management delivers a dramatic reset of its own.

Catalysts and Risks: What to Watch for the Next Expectation Shift

The current price action for these software stocks is a snapshot of where expectations stand. The next moves will hinge on specific catalysts and risks that either confirm or challenge the prevailing market view.

For Doximity, the key watchpoint is whether its massive AI adoption can drive growth to meet the new $500 million share repurchase program. The company has already demonstrated strong user traction, with 300,000 unique prescriber users on DocsGPT in its first full quarter post-acquisition. The market is now pricing in a 10% revenue growth rate and a 16x exit P/E to support a 30% total upside. The risk is that the weak Q4 guidance, driven by delayed pharma budgets, creates a multi-quarter growth drag that makes it difficult to justify the repurchase authorization. The stock's ability to hold above its recent lows will signal whether investors believe the AI momentum can overcome this near-term headwind.

Guidewire Software's catalyst is imminent. The company's stock is already up 6% on anticipation, but the March 5, 2026 earnings call will test if its cloud momentum can justify its premium valuation. The market is looking past the past quarter to the forward view, with the key metric being its cloud ARR growth of 22%. The risk is that the upcoming print, while likely strong, fails to accelerate enough to support the current optimism. A guidance raise or a clear path to higher growth would be needed to sustain the "buy the rumor" rally. If the report is merely in line, the stock could face a "sell the news" event.

Health Catalyst's setup is one of extreme pessimism. The stock is trading near its 52-week low and below its 200-day simple moving average. The primary catalyst for a shift would be a break above this key technical level, signaling a reversal in the downtrend. The company's financials show a net loss, but with a trailing net revenue retention rate of 112% and 90%+ gross margins, the business model has strength. The risk is that without a clear catalyst from management or a broader sector rotation, the market will continue to price in continued struggles, leaving the stock vulnerable to further disappointment.

For Bentley Systems, the watchpoint is whether its strong operational metrics translate into accelerating stock performance. The company has delivered consistent execution, with constant currency ARR growth at 11.5% and improving operating margins. The risk is that this steady expansion is now the new baseline, not a surprise. The stock's underperformance suggests the market is waiting for a catalyst beyond organic growth-perhaps a major acquisition or a clearer path to higher margins-that could drive the stock higher. Without such a catalyst, the current price may reflect a "hold" view on steady but unspectacular execution.